View in EDS

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Saved in:
Bibliographic Details
Title: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Authors: Morgans AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chehrazi-Raffle A; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Niazi T; Division of Radiation Oncology, Department of Oncology, Mcgill University, Montreal, QC, Canada., Shore ND; START carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA., Ross AE; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Røder A; Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Gomes AJ; Liga Norte Riograndense Contra O Cancer, Natal, Brazil., Supiot S; Department of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Barthélémy P; Medical Oncology Department, University Hospital of Strasbourg, Strasbourg, France., Hatano K; Department of Urology, Graduate School of Medicine, The University of Osaka, Osaka, Japan., Ruiz CBC; Urology and Nephrology Department, Virgen Del Rocío University Hospital, Seville, Spain., Yoshida S; Department of Urology, Institute of Science Tokyo, Tokyo, Japan., Herrera-Imbroda B; Virgen de la Victoria Hospital, Urology Unit, ibima-Plataforma Bionand, Malaga, Spain., Gratton M; Hôpital Hôtel-Dieu de Lévis, Lévis, QC, Canada., Gschwend JE; TUM Klinikum, Rechts der Isar, Technical University Munich, Munich, Germany., Hope TA; Department of Radiology and Biomedical Imaging, University of San Francisco, San Francisco, CA, USA., Joensuu H; Orion Corporation, Orion Pharma, Espoo, Finland., Kuss I; Bayer AG, Berlin, Germany., Le Berre MA; Bayer Healthcare SAS, Lille, France., Dimova-Dobreva M; Bayer Consumer Care AG, Basel, Switzerland., Fizazi K; Centre Oscar Lambret, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Source: Future oncology (London, England) [Future Oncol] 2025 Nov; Vol. 21 (27), pp. 3491-3498. Date of Electronic Publication: 2025 Nov 11.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41216639
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Morgans+AK%22">Morgans AK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chehrazi-Raffle+A%22">Chehrazi-Raffle A</searchLink>; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Niazi+T%22">Niazi T</searchLink>; Division of Radiation Oncology, Department of Oncology, Mcgill University, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Shore+ND%22">Shore ND</searchLink>; START carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA.<br /><searchLink fieldCode="AU" term="%22Ross+AE%22">Ross AE</searchLink>; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Røder+A%22">Røder A</searchLink>; Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Gomes+AJ%22">Gomes AJ</searchLink>; Liga Norte Riograndense Contra O Cancer, Natal, Brazil.<br /><searchLink fieldCode="AU" term="%22Supiot+S%22">Supiot S</searchLink>; Department of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.<br /><searchLink fieldCode="AU" term="%22Barthélémy+P%22">Barthélémy P</searchLink>; Medical Oncology Department, University Hospital of Strasbourg, Strasbourg, France.<br /><searchLink fieldCode="AU" term="%22Hatano+K%22">Hatano K</searchLink>; Department of Urology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Ruiz+CBC%22">Ruiz CBC</searchLink>; Urology and Nephrology Department, Virgen Del Rocío University Hospital, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Yoshida+S%22">Yoshida S</searchLink>; Department of Urology, Institute of Science Tokyo, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Herrera-Imbroda+B%22">Herrera-Imbroda B</searchLink>; Virgen de la Victoria Hospital, Urology Unit, ibima-Plataforma Bionand, Malaga, Spain.<br /><searchLink fieldCode="AU" term="%22Gratton+M%22">Gratton M</searchLink>; Hôpital Hôtel-Dieu de Lévis, Lévis, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Gschwend+JE%22">Gschwend JE</searchLink>; TUM Klinikum, Rechts der Isar, Technical University Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Hope+TA%22">Hope TA</searchLink>; Department of Radiology and Biomedical Imaging, University of San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Joensuu+H%22">Joensuu H</searchLink>; Orion Corporation, Orion Pharma, Espoo, Finland.<br /><searchLink fieldCode="AU" term="%22Kuss+I%22">Kuss I</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Le+Berre+MA%22">Le Berre MA</searchLink>; Bayer Healthcare SAS, Lille, France.<br /><searchLink fieldCode="AU" term="%22Dimova-Dobreva+M%22">Dimova-Dobreva M</searchLink>; Bayer Consumer Care AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fizazi+K%22">Fizazi K</searchLink>; Centre Oscar Lambret, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2025 Nov; Vol. 21 (27), pp. 3491-3498. <i>Date of Electronic Publication: </i>2025 Nov 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial Protocol
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41216639
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2025.2577633
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3491
    Titles:
      – TitleFull: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Morgans AK
      – PersonEntity:
          Name:
            NameFull: Chehrazi-Raffle A
      – PersonEntity:
          Name:
            NameFull: Niazi T
      – PersonEntity:
          Name:
            NameFull: Shore ND
      – PersonEntity:
          Name:
            NameFull: Ross AE
      – PersonEntity:
          Name:
            NameFull: Røder A
      – PersonEntity:
          Name:
            NameFull: Gomes AJ
      – PersonEntity:
          Name:
            NameFull: Supiot S
      – PersonEntity:
          Name:
            NameFull: Barthélémy P
      – PersonEntity:
          Name:
            NameFull: Hatano K
      – PersonEntity:
          Name:
            NameFull: Ruiz CBC
      – PersonEntity:
          Name:
            NameFull: Yoshida S
      – PersonEntity:
          Name:
            NameFull: Herrera-Imbroda B
      – PersonEntity:
          Name:
            NameFull: Gratton M
      – PersonEntity:
          Name:
            NameFull: Gschwend JE
      – PersonEntity:
          Name:
            NameFull: Hope TA
      – PersonEntity:
          Name:
            NameFull: Joensuu H
      – PersonEntity:
          Name:
            NameFull: Kuss I
      – PersonEntity:
          Name:
            NameFull: Le Berre MA
      – PersonEntity:
          Name:
            NameFull: Dimova-Dobreva M
      – PersonEntity:
          Name:
            NameFull: Fizazi K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 27
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1